4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Evommune, Inc. (EVMN) operates in the Biotechnology industry and is headquartered in Palo Alto, United States with about 48 employees. Its market capitalization is roughly $488 million. In the fiscal year ended 2025-12-31, EVMN reported $13M in revenue and ($69M) in net income.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Interactive charts & full statements → Open the EVMN valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | $13M | — |
| Operating Income (EBIT) | ($81M) | — |
| Net Income | ($69M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $10M | $0M |
| Operating Income (EBIT) | ($24M) | ($30M) | ($13M) | ($22M) |
| Net Income | ($22M) | ($28M) | ($12M) | ($21M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | $225M | — |
| Total Liabilities | $19M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EVMN viewer.
About TickerBase · Data methodology & sources